Latest Medical Technology News

Paragon Care Limited reported solid FY25 results with revenue climbing to $3.61 billion and underlying EBITDA rising 3%, driven by successful integration and expansion into new healthcare segments.

EBOS Group Limited reported solid FY25 results with 12% revenue growth and strategic acquisitions, setting sights on continued expansion and operational efficiency in FY26.

EBOS Group Limited reported a steady FY25 with 12% revenue growth and EBITDA in line with guidance, driven by strong healthcare and animal care segments. The company signals confidence with maintained dividends and a positive FY26 outlook.

Artrya Limited has secured FDA 510(k) clearance for its Salix Coronary Plaque module, enabling near real-time detection of high-risk coronary artery plaque and opening a lucrative U.S. market opportunity with a $950 reimbursement per scan.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.30 per share for the fiscal year ending June 30, 2025, signaling steady returns for shareholders.

Tetratherix has landed a $3.3 million Australian Government grant to co-fund a $7.4 million project expanding its synthetic polymer production and supporting its US market entry in 2026.

Altitude Minerals has identified significant concentrations of zircon and titanium minerals in new samples from its EL7071 tenement in South Australia's Eromanga Basin, setting the stage for a planned drilling campaign in September 2025.

Memphasys Limited pivots from development to commercial execution with its flagship IVF product Felix, targeting global markets through direct sales and recurring revenue streams.

Next Science reports a 10% decline in quarterly product sales but advances a $50 million asset sale to Demetra Holdings, signaling a pivotal shift in its business strategy.

PolyNovo Limited reports a robust FY25 with nearly 29% sales growth, a significant cash increase to A$33.5 million, and expanding global market presence. The company’s strategic investments and product innovations signal strong momentum ahead.

Osteopore Limited reports a three-fold increase in craniofacial implant sales within a year of signing an exclusive distribution deal with Zimmer Biomet, signaling strong early traction across key global markets.